The association between multimorbidity and mobility disability-free life expectancy in adults aged 85 years and over: A modelling study in the Newcastle 85+ cohort.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
29
04
2022
accepted:
20
10
2022
entrez:
14
11
2022
pubmed:
15
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Mobility disability is predictive of further functional decline and can itself compromise older people's capacity (and preference) to live independently. The world's population is also ageing, and multimorbidity is the norm in those aged ≥85. What is unclear in this age group, is the influence of multimorbidity on (a) transitions in mobility disability and (b) mobility disability-free life expectancy (mobDFLE). Using multistate modelling in an inception cohort of 714 85-year-olds followed over a 10-year period (aged 85 in 2006 to 95 in 2016), we investigated the association between increasing numbers of long-term conditions and (1) mobility disability incidence, (2) recovery from mobility disability and (3) death, and then explored how this shaped the remaining life expectancy free from mobility disability at age 85. Models were adjusted for age, sex, disease group count, BMI and education. We defined mobility disability based on participants' self-reported ability to get around the house, go up and down stairs/steps, and walk at least 400 yards; participants were defined as having mobility disability if, for one or more these activities, they had any difficulty with them or could not perform them. Data were drawn from the Newcastle 85+ Study: a longitudinal population-based cohort study that recruited community-dwelling and institutionalised individuals from Newcastle upon Tyne and North Tyneside general practices. We observed that each additional disease was associated with a 16% increased risk of incident mobility disability (hazard ratio (HR) 1.16, 95% confidence interval (CI): 1.07 to 1.25, p < 0.001), a 26% decrease in the chance of recovery from this state (HR 0.74, 95% CI: 0.63 to 0.86, p < 0.001), and a 12% increased risk of death with mobility disability (HR: 1.12, 95% CI: 1.07- to .17, p < 0.001). This translated to reductions in mobDFLE with increasing numbers of long-term conditions. However, residual and unmeasured confounding cannot be excluded from these analyses, and there may have been unobserved transitions to/from mobility disability between interviews and prior to death. We suggest 2 implications from this work. (1) Our findings support calls for a greater focus on the prevention of multimorbidity as populations age. (2) As more time spent with mobility disability could potentially lead to greater care needs, maintaining independence with increasing age should also be a key focus for health/social care and reablement services.
Sections du résumé
BACKGROUND
Mobility disability is predictive of further functional decline and can itself compromise older people's capacity (and preference) to live independently. The world's population is also ageing, and multimorbidity is the norm in those aged ≥85. What is unclear in this age group, is the influence of multimorbidity on (a) transitions in mobility disability and (b) mobility disability-free life expectancy (mobDFLE).
METHODS AND FINDINGS
Using multistate modelling in an inception cohort of 714 85-year-olds followed over a 10-year period (aged 85 in 2006 to 95 in 2016), we investigated the association between increasing numbers of long-term conditions and (1) mobility disability incidence, (2) recovery from mobility disability and (3) death, and then explored how this shaped the remaining life expectancy free from mobility disability at age 85. Models were adjusted for age, sex, disease group count, BMI and education. We defined mobility disability based on participants' self-reported ability to get around the house, go up and down stairs/steps, and walk at least 400 yards; participants were defined as having mobility disability if, for one or more these activities, they had any difficulty with them or could not perform them. Data were drawn from the Newcastle 85+ Study: a longitudinal population-based cohort study that recruited community-dwelling and institutionalised individuals from Newcastle upon Tyne and North Tyneside general practices. We observed that each additional disease was associated with a 16% increased risk of incident mobility disability (hazard ratio (HR) 1.16, 95% confidence interval (CI): 1.07 to 1.25, p < 0.001), a 26% decrease in the chance of recovery from this state (HR 0.74, 95% CI: 0.63 to 0.86, p < 0.001), and a 12% increased risk of death with mobility disability (HR: 1.12, 95% CI: 1.07- to .17, p < 0.001). This translated to reductions in mobDFLE with increasing numbers of long-term conditions. However, residual and unmeasured confounding cannot be excluded from these analyses, and there may have been unobserved transitions to/from mobility disability between interviews and prior to death.
CONCLUSIONS
We suggest 2 implications from this work. (1) Our findings support calls for a greater focus on the prevention of multimorbidity as populations age. (2) As more time spent with mobility disability could potentially lead to greater care needs, maintaining independence with increasing age should also be a key focus for health/social care and reablement services.
Identifiants
pubmed: 36374907
doi: 10.1371/journal.pmed.1004130
pii: PMEDICINE-D-22-01444
pmc: PMC9662726
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1004130Subventions
Organisme : Department of Health
ID : NIHR200173
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : G0500997
Pays : United Kingdom
Organisme : Department of Health
ID : NF-SI-0616019954
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0500997
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J50001X/1
Pays : United Kingdom
Informations de copyright
Copyright: © 2022 Davies et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Exerc Sport Sci Rev. 2013 Jan;41(1):2
pubmed: 23262463
PLoS One. 2014 Feb 07;9(2):e88016
pubmed: 24516578
Biomed Res Int. 2016;2016:8745670
pubmed: 26885519
Lancet Public Health. 2021 Aug;6(8):e587-e597
pubmed: 34166630
Ann Intern Med. 2012 Jan 17;156(2):131-40
pubmed: 22250144
BMC Geriatr. 2011 May 04;11:21
pubmed: 21542901
Age Ageing. 2018 May 01;47(3):374-380
pubmed: 29370339
Comput Methods Programs Biomed. 2019 Sep;178:11-18
pubmed: 31416539
Am J Epidemiol. 1993 Apr 15;137(8):845-57
pubmed: 8484376
Obes Rev. 2010 Aug;11(8):568-79
pubmed: 20059707
Age Ageing. 2022 Oct 6;51(10):
pubmed: 36309974
PLoS One. 2012;7(2):e31665
pubmed: 22355385
J Intern Med. 2019 Mar;285(3):255-271
pubmed: 30357990
Milbank Q. 1989;67(3-4):450-84
pubmed: 2534562
J Clin Epidemiol. 1999 Jan;52(1):27-37
pubmed: 9973071
Biometrics. 2000 Mar;56(1):244-8
pubmed: 10783802
Lancet. 2016 Feb 20;387(10020):779-86
pubmed: 26680218
J Epidemiol Community Health. 2021 Mar;75(3):242-244
pubmed: 33020144
PLoS One. 2021 Mar 11;16(3):e0245193
pubmed: 33705429
Soc Sci Med. 1994 Jan;38(1):1-14
pubmed: 8146699
Popul Trends. 2005 Summer;(120):15-22
pubmed: 16025700
EClinicalMedicine. 2021 Jul 31;39:101041
pubmed: 34386756
BMJ. 2009 Dec 22;339:b4904
pubmed: 20028777
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
Drug Discov Today. 2020 Aug;25(8):1403-1415
pubmed: 32574698
Soc Sci Med. 1996 Dec;43(11):1601-10
pubmed: 8961404
J Am Geriatr Soc. 2006 Feb;54(2):248-54
pubmed: 16460375
PLoS One. 2014 Oct 10;9(10):e108370
pubmed: 25302500
BMC Geriatr. 2010 Sep 17;10:64
pubmed: 20849598
J Intern Med. 2009 Feb;265(2):288-95
pubmed: 19192038
Epidemiol Rev. 2013;35:75-83
pubmed: 23372025
JAMA. 2013 Sep 18;310(11):1168-77
pubmed: 24045741
J Gerontol A Biol Sci Med Sci. 2017 Aug 01;72(8):1117-1122
pubmed: 27753610
BMC Med. 2017 Aug 24;15(1):152
pubmed: 28835246
BMC Geriatr. 2007 Jun 26;7:14
pubmed: 17594470
J Am Geriatr Soc. 2020 Apr;68(4):872-881
pubmed: 32105353
Arch Gerontol Geriatr. 2015 May-Jun;60(3):405-11
pubmed: 25747850
J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):408-14
pubmed: 17452735
Aging Male. 2002 Mar;5(1):1-37
pubmed: 12040973
Lancet. 2017 Oct 7;390(10103):1676-1684
pubmed: 28821408